KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Other Accumulated Expenses (2016 - 2026)

Bio-Rad Laboratories has reported Other Accumulated Expenses over the past 18 years, most recently at $153.9 million for Q1 2026.

  • Quarterly Other Accumulated Expenses rose 16.86% to $153.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $153.9 million through Mar 2026, up 16.86% year-over-year, with the annual reading at $141.7 million for FY2025, 3.74% down from the prior year.
  • Other Accumulated Expenses was $153.9 million for Q1 2026 at Bio-Rad Laboratories, up from $141.7 million in the prior quarter.
  • Over five years, Other Accumulated Expenses peaked at $212.7 million in Q2 2022 and troughed at $127.8 million in Q3 2025.
  • The 5-year median for Other Accumulated Expenses is $153.9 million (2026), against an average of $160.0 million.
  • Year-over-year, Other Accumulated Expenses skyrocketed 37.29% in 2022 and then decreased 21.85% in 2023.
  • A 5-year view of Other Accumulated Expenses shows it stood at $169.6 million in 2022, then fell by 4.74% to $161.6 million in 2023, then decreased by 8.91% to $147.2 million in 2024, then fell by 3.74% to $141.7 million in 2025, then increased by 8.61% to $153.9 million in 2026.
  • Per Business Quant, the three most recent readings for BIO's Other Accumulated Expenses are $153.9 million (Q1 2026), $141.7 million (Q4 2025), and $127.8 million (Q3 2025).